A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
NCT01194570
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
735
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
DRUG:
Ocrelizumab
OTHER:
Placebo
Sponsor
Hoffmann-La Roche